<DOC>
	<DOCNO>NCT01584557</DOCNO>
	<brief_summary>The purpose study evaluate short term efficacy safety tolvaptan subject hospitalize worsen heart failure volume overload one following : renal insufficiency , hyponatremia inadequate response diuretic therapy . The primary variable assess efficacy self-assessed 7-point dyspnea score 8 16 hour .</brief_summary>
	<brief_title>Randomized , Double-Blind , Placebo Controlled Study Short Term Clinical Effects Tolvaptan Patients Hospitalized Worsening Heart Failure With Challenging Volume Management</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Tolvaptan</mesh_term>
	<criteria>1 . Subjects hospitalize worsen heart failure randomize within 36 hour initial presentation . 2 . Males females 18 year age old . 3 . NYHA Class III IV admission hospital . 4 . Able understand content willing provide write informed consent 5 . Dyspnea , measure 5point current dyspnea scale ( moderately short breath worse ) , within 2 hour randomization dose . The following must meet within 12 hour randomization . 6 . The subject must sign extracellular volume expansion , define two follow five : Signs RHF ( jugular venous distention , pit edema ( ≥1+ ) , ascites ) and/or Signs LHF ( pulmonary congestion chest xray , pulmonary rale ) 7 . Have least one following : eGFR &lt; 60ml/min/1.73m2 , OR serum sodium ≤ 134 mEq/L , OR urine output ≤ 125 ml/hr anytime frame least 2 hour , follow administration IV furosemide least 40mg . See table . Time Period ( hr ) Cumulative UO ( mL ) 2 &lt; 250 3 &lt; 375 4 &lt; 500 5 &lt; 625 6 &lt; 750 7 &lt; 875 8 &lt; 1000 1 . Positive urine pregnancy test woman child bear potential . 2 . Inability provide write informed consent . 3 . Cardiac surgery within 60 day prior study randomization . 4 . Acute Coronary Syndrome ( ACS ) percutaneous coronary intervention within 30 day prior study randomization . 5 . Planned revascularization procedure , cardiac mechanical support implantation , cardiac transplantation , cardiac surgery within 30 day follow study randomization . 6 . Planned electrophysiologic ( EP ) device implantation within 7 day follow study randomization . 7 . Subjects cardiac mechanical support . 8 . Comorbid condition expect survival less six month . 9 . History cerebrovascular accident within last 30 day . 10 . Hemodynamically significant uncorrected primary cardiac valvular disease . 11 . Hypertrophic cardiomyopathy ( obstructive nonobstructive ) . 12 . Uncorrected thyroid disease , active myocarditis know amyloid cardiomyopathy . 13 . History primary significant liver disease acute hepatic failure , define investigator . 14 . Chronic uncontrolled diabetes mellitus determine investigator . 15 . Supine systolic arterial blood pressure &lt; 90 mmHg . 16 . Serum creatinine &gt; 3.5 mg/dL undergoing dialysis . 17 . Hemoglobin &lt; 9 g/dL 18 . History hypersensitivity and/or idiosyncratic reaction benzazepine derivative ( benazepril ) . 19 . Inability take oral medication . 20 . Participation another clinical drug device trial last dose drug within past 30 day investigational medical device currently implant . 21 . Previous exposure tolvaptan within 7 day prior randomization . 22 . Subjects refractory , endstage , heart failure define subject appropriate candidate specialize treatment strategy , ventricular assist device , continuous positive IV inotropic therapy , hospice care . 23 . Ultrafiltration within 7 day prior randomization plan . 24 . Active gout 25 . Serum sodium &gt; 144 mEq/L</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>